583 related articles for article (PubMed ID: 22824822)
1. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
2. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
3. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging targeted therapies for metastatic breast cancer.
Perez EA; Spano JP
Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
[TBL] [Abstract][Full Text] [Related]
6. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
7. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
Brufsky A
Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
[TBL] [Abstract][Full Text] [Related]
12. HER2-directed therapy for metastatic breast cancer.
Jelovac D; Emens LA
Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
[TBL] [Abstract][Full Text] [Related]
13. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
14. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
15. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
19. Improving treatment of HER2-positive cancers: opportunities and challenges.
Stern HM
Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
[TBL] [Abstract][Full Text] [Related]
20. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
